期刊
NEUROPSYCHOPHARMACOLOGY
卷 36, 期 2, 页码 411-422出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/npp.2010.172
关键词
chronic pain; opioid abuse; oxycodone; buprenorphine; suboxone; self-administration
资金
- National Institute on Drug Abuse [DA020448]
- Reckitt-Benckiser Pharmaceuticals
- Schering-Plough Corporation
- Johnson & Johnson Pharmaceutical Research Development
- Endo Pharmaceuticals
- Avigen
- NATIONAL INSTITUTE ON DRUG ABUSE [R01DA020448] Funding Source: NIH RePORTER
Some sources suggest that significant misuse of opioid drugs exists among patients with chronic pain. However, the risk factors and motivation behind their abuse may differ from those of other opioid abusers. This study sought to examine the abuse liability of oxycodone among patients with chronic, non-malignant pain who met the DSM-IV criteria for opioid abuse. Eighteen opioid-dependent patients with chronic pain lived on an in-patient unit of the New York State Psychiatric Institute during the 7-week study. Participants were given oral oxycodone (0, 10, 20, 40, and 60 mg/70 kg) while maintained on various doses of sublingual buprenorphine/naloxone (Bup/Nx; 2/0.5, 8/2, and 16/4 mg/day). Doses of both medications were administered under double-blind conditions. Oxycodone produced an overall positive, but less robust, subjective profile than previously reported in recreational opioid users without pain. Furthermore, unlike our findings in recreational opioid users and more similar to effects in non-drug-abusing individuals, oxycodone failed to serve as a reinforcer. As for the maintenance drug, Bup/Nx produced a dose-related reduction in some of the effects of acutely administered oxycodone. These data suggest that sublingual Bup/Nx has the potential as an analgesic medication and further research should investigate its use in treating patients with chronic pain who abuse opioids. Neuropsychopharmacology (2011) 36, 411-422; doi:10.1038/npp.2010.172; published online 27 October 2010
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据